BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32363681)

  • 21. Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease.
    Marcum ZA; Forsberg CW; Moore KP; de Boer IH; Smith NL; Boyko EJ; Floyd JS
    J Gen Intern Med; 2018 Feb; 33(2):155-165. PubMed ID: 29181788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metformin Cessation and Dementia Incidence.
    Zimmerman SC; Ferguson EL; Choudhary V; Ranatunga DK; Oni-Orisan A; Hayes-Larson E; Duarte Folle A; Mayeda ER; Whitmer RA; Gilsanz P; Power MC; Schaefer C; Glymour MM; Ackley SF
    JAMA Netw Open; 2023 Oct; 6(10):e2339723. PubMed ID: 37878309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
    Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
    Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin and the risk of endometrial cancer: a population-based cohort study.
    Ko EM; Stürmer T; Hong JL; Castillo WC; Bae-Jump V; Funk MJ
    Gynecol Oncol; 2015 Feb; 136(2):341-7. PubMed ID: 25499603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus.
    Newby D; Linden AB; Fernandes M; Molero Y; Winchester L; Sproviero W; Ghose U; Li QS; Launer LJ; Duijn CMV; Nevado-Holgado AJ
    BMJ Open Diabetes Res Care; 2022 Sep; 10(5):. PubMed ID: 36109050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycemic Control and Insulin Treatment Alter Fracture Risk in Older Men With Type 2 Diabetes Mellitus.
    Lee RH; Sloane R; Pieper C; Lyles KW; Adler RA; Van Houtven C; LaFleur J; Colón-Emeric C
    J Bone Miner Res; 2019 Nov; 34(11):2045-2051. PubMed ID: 31269274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.
    Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Griffin MR
    BMC Endocr Disord; 2016 Jun; 16(1):32. PubMed ID: 27255309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
    Kowall B; Stang A; Rathmann W; Kostev K
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of antidiabetic medications and risk of chronic obstructive pulmonary disease exacerbation requiring hospitalization: a disease risk score-matched nested case-control study.
    Wang MT; Lai JH; Huang YL; Kuo FC; Wang YH; Tsai CL; Tu MY
    Respir Res; 2020 Dec; 21(1):319. PubMed ID: 33267895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
    Filion KB; Douros A; Azoulay L; Yin H; Yu OH; Suissa S
    Br J Clin Pharmacol; 2019 Oct; 85(10):2378-2389. PubMed ID: 31276600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
    Matthews DR; Paldánius PM; Proot P; Chiang Y; Stumvoll M; Del Prato S;
    Lancet; 2019 Oct; 394(10208):1519-1529. PubMed ID: 31542292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus.
    Shi Q; Liu S; Fonseca VA; Thethi TK; Shi L
    BMJ Open; 2019 Jul; 9(7):e024954. PubMed ID: 31366635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus.
    Toriola AT; Luo S; Thomas TS; Drake BF; Chang SH; Sanfilippo KM; Carson KR
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):169-175. PubMed ID: 31685560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent metformin adherence and the risk of hypoglycaemia in the year following intensification with a sulfonylurea.
    Min JY; Griffin MR; Chipman J; Hackstadt AJ; Greevy RA; Grijalva CG; Hung AM; Roumie CL
    Diabet Med; 2019 Apr; 36(4):482-490. PubMed ID: 30378161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study.
    Thomsen RW; Baggesen LM; Svensson E; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetes Obes Metab; 2015 Aug; 17(8):771-80. PubMed ID: 25929277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.
    Calip GS; Yu O; Elmore JG; Boudreau DM
    Cancer Causes Control; 2016 May; 27(5):709-20. PubMed ID: 27053250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
    Fonseca V; Gill J; Zhou R; Leahy J
    Diabetes Obes Metab; 2011 Sep; 13(9):814-22. PubMed ID: 21481127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
    Kowall B; Rathmann W; Kostev K
    Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.